Analysts Set Senseonics Holdings, Inc. (NYSE:SENS) PT at $1.54

Senseonics Holdings, Inc. (NYSE:SENS) has received an average rating of “Buy” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $1.5375.

SENS has been the topic of several research analyst reports. HC Wainwright restated a “buy” rating and issued a $1.40 price objective (up from $1.10) on shares of Senseonics in a research report on Tuesday, July 8th. TD Cowen began coverage on Senseonics in a research note on Tuesday, July 15th. They set a “buy” rating and a $1.25 target price on the stock. Lake Street Capital upgraded Senseonics to a “strong-buy” rating in a research note on Thursday, July 17th. Finally, Barclays initiated coverage on shares of Senseonics in a report on Wednesday, August 27th. They set an “overweight” rating and a $1.50 price objective for the company.

Senseonics Stock Down 2.1%

SENS opened at $0.46 on Friday. The stock has a market cap of $374.75 million, a price-to-earnings ratio of -3.54 and a beta of 0.93. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The firm’s fifty day moving average is $0.48 and its 200 day moving average is $0.55. Senseonics has a fifty-two week low of $0.25 and a fifty-two week high of $1.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Northern Trust Corp increased its holdings in shares of Senseonics by 11.2% in the fourth quarter. Northern Trust Corp now owns 1,194,960 shares of the company’s stock worth $625,000 after purchasing an additional 120,441 shares during the last quarter. Millennium Management LLC grew its holdings in Senseonics by 299.0% during the 4th quarter. Millennium Management LLC now owns 1,088,029 shares of the company’s stock valued at $569,000 after buying an additional 815,332 shares in the last quarter. Two Sigma Investments LP bought a new stake in Senseonics in the 4th quarter worth approximately $36,000. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Senseonics by 679.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 289,919 shares of the company’s stock worth $190,000 after acquiring an additional 252,745 shares in the last quarter. Finally, Ridgecrest Wealth Partners LLC boosted its position in shares of Senseonics by 160.9% during the 1st quarter. Ridgecrest Wealth Partners LLC now owns 300,000 shares of the company’s stock valued at $197,000 after acquiring an additional 185,000 shares during the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.